In this manner, patients with HFpEF may be eligible for cardioprotectivetreatment with SGLT2 inhibitors when considering the presence of nephropathy ortheir diabetes status, and not only according to HFpEF criteria. This evidence concerns the gene SLC5A2 and diabetes mellitus.